Rubius Therapeutics (RUBY) Tops Q4 EPS by 4c

Rubius Therapeutics (NASDAQ: RUBY) reported Q4 EPS of ($0.56), $0.04 better than the analyst estimate of ($0.60).

“Over the past two years, we have generated exciting oncology preclinical data, demonstrating the ability of our Red Cell Therapeutics to both broadly activate the immune system, and induce tumor-specific responses by activating and expanding antigen-specific T cells with our artificial antigen-presenting cells. By focusing on the development of our oncology and autoimmune pipeline, we believe we will have the greatest opportunity to bring life-saving therapies to patients, enhance shareholder value and extend our cash runway into 2022,” said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics. “With our internal cGMP manufacturing established, we are well positioned to advance this entirely new class of allogeneic cellular medicines.”

For earnings history and earnings-related data on Rubius Therapeutics (RUBY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c